Topiramate for the prophylaxis of episodic migraine in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Linde, Mattias ^a   Mulleners, Wim M ^b   Chronicle, Edward P ^c   Mccrory, Douglas C ^d,e  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c UNIVERSITY OF HAWAII   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; FLUNARIZINE; PLACEBO; PROPRANOLOL; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

ADULT; AGED; ANALGESIA; ANOREXIA; BODY WEIGHT LOSS; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; EMOTION; EPISODIC MIGRAINE; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL HEALTH; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; REVIEW; ROLE PLAYING; SHORT FORM 36; SOCIAL INTERACTION; SYSTEMATIC REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; META ANALYSIS; MIGRAINE; ANALOGS AND DERIVATIVES; MIGRAINE DISORDERS;

ADULT; ANTICONVULSANTS; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84888383924     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010610     Document Type: Review

References (75)

1. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience 2012;122(2):60-8. [MEDLINE: 21950578]
2. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurologica Scandinavica 2008;118(5):301-5. [MEDLINE: 18713156]
3. Brandes JL, Kudrow DB, Rothrock JF, Rupnow MFT, Fairclough DL, Greenberg SJ. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings 2006;81(10):1311-9. [MEDLINE: 17036556]
4. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291(8):965-73. [MEDLINE: 14982912]
5. de Tommaso M, Guido M, Sardaro M, Serpino C, Vecchio E, De Stefano G, et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neuroscience Letters 2008;442(2):81-5. [MEDLINE: 18620023]
6. de Tommaso M, Marinazzo D, Nitti L, Pellicoro M, Guido M, Serpino C, et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clinical Neurophysiology 2007;118(10):2297-304. [MEDLINE: 17709295]
7. Diener HC, Tfelt-Hansen P, Dahlöf C, Lainez MJA, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. Journal of Neurology 2004;251(8):943-50. [MEDLINE: 15316798]
8. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2007;6(12):1054-62. [MEDLINE: 17988947]
9. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al. for the CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clinical Therapeutics 2009;31(3):542-59. [MEDLINE: 19393844]
10. Edwards KR, Glantz MJ, Norton JA, Cross N. Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients. Cephalalgia 2000;20(4):316. [DOI: 10.1046/j.1468-2982.2000.00204.x]
11. Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007;47(3):402-12. [MEDLINE: 17371357]
12. Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia 2011;31(1):18-30. [MEDLINE: 20974598]
13. Luo N, Di W, Zhang A, Wang Y, Ding M, Qi W, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine 2012;13(1):80-6. [MEDLINE: 22233396]
14. Mei D, Capuano A, Vollono C, Evangelista M, Ferraro D, Tonali P, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurological Sciences 2004;25(5):245-50. [MEDLINE: 15624081]
15. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46(4):642-8. [MEDLINE: 16643559]
16. Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research & Opinion 2006;22(6):1021-9. [MEDLINE: 16846536]
17. Silberstein SD, Neto W, Schmitt J, Jacobs D, for the MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology 2004;61(4):490-5. [MEDLINE: 15096395]
18. Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clinical Therapeutics 2006;28(7):1002-11. [MEDLINE: 16990078]
19. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41(10):968-75. [MEDLINE: 11903524]
20. Varkey E, Cider Å, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia 2011;31(14):1428-38. [MEDLINE: 21890526]
21. Bartolini M, Silvestrini M, Taffi R, Lanciotti C, Luconi R, Capecci M, et al. Efficacy of topiramate and valproate in chronic migraine. Clinical Neuropharmacology 2005;28(6):277-9. [MEDLINE: 16340383]
22. Bavrasad R, Nejad SEM, Yarahmadi AR, Sajedi SI, Rahim F. Assessment of the middle dose of topiramate in comparison with sodium valproate for migraine prophylaxis: a randomized-double-blind study. International Journal of Pharmacology 2010;6(5):670-5. [EMBASE: 2010449325]
23. Cady RK, Voirin J, Farmer K, Browning R, Beach ME, Tarrasch J. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications. Headache 2012;52(5):749-64. [MEDLINE: 22188311]
24. Cazares M, Leal R, Cardiel M, Ibarra O, Garcia M. Essay controlled by drawing, crossed, to evaluate the efficiency and safety of amitriptyline against topiramate in the prevention of the migraine [Ensayo controlado por sorteo, cruzado, para evaluar la eficacia y seguridad de amitriptilina contra topiramato en la prevención de la migraña]. Revista Mexicana de Neurociencia 2008;9(6):475-9.
25. Cutrer FM. Antiepileptic drugs: how they work in headache. Headache 2001;41 Suppl 1:S3-S10.
26. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Topiramate as prophylactic treatment in migraine [Topiramate nella terapia di profilassi dell'emicrania]. Acta Medica Romana 2000;38(1-2):164-8.
27. Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectrums 2003;8(6):428-32. [MEDLINE: 12858132]
28. Freitag FG. Topiramate prophylaxis in patients suffering from migraine with aura: results from a randomized, double-blind, placebo-controlled trial. Advanced Studies in Medicine 2003;3(6C):S562-4.
29. Garcia-Monco JC, Foncea N, Bilbao A, Ruiz De Velasco I, Gomez-Beldarrain M. Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. Cephalalgia 2007;27(8):920-8. [MEDLINE: 17645757]
30. Gode S, Celebisoy N, Kirazli T, Akyuz A, Bilgen C, Karapolat H, et al. Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache 2010;50(1):77-84. [MEDLINE: 19656221]
31. Hart CE, Dodick DW, Brandes JL, Rothrock JF, Jacobs D, Neto W, et al. Migraine prophylaxis with topiramate: results of double-blind, placebo-controlled, dose-response trials. Epilepsia 2003;44 Suppl 9:106-7.
32. Huntington J, Yuan CL. Topiramate (Topamax) for migraine prevention. American Family Physician 2005;72(8):1563-5. [EMBASE: 2006032188]
33. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clinical Neurology & Neurosurgery 2008;110(10):979-84. [MEDLINE: 18620801]
34. Krymchantowski AV, Jevoux CC. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study. Headache 2011;51(4):554-8. [EMBASE: 2011188025]
35. Krymchantowski AV, Da Cunha Jevoux C, Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. Journal of Headache & Pain 2012;13(1):53-9. [MEDLINE: 22008899]
36. Li ZX, Li XG, Xiong XJ, Zhang ZL. A clinical study of sibelium combining topiramate in prophylactic treatment of migraine [original in Chinese]. Chinese Journal of Modern Applied Pharmacy 2002;19(5):419-21.
37. Li HL, Kwan P, Leung H, Yu E, Tsoi TH, Hui ACF, et al. Topiramate for migraine prophylaxis among Chinese population. Headache 2007;47(4):616-9. [EMBASE: 2007195566]
38. Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clinical Pharmacology & Therapeutics 2009;85(3):283-8. [MEDLINE: 18987621]
39. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Gutierrez I, Rivera-Castano L, Trujillo-Hernandez B, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. European Neurology 2008;59(5):237-42. [MEDLINE: 18264012]
40. Mohammadianinejad SE, Abbasi V, Sajedi SA, Majdinasab N, Abdollahi F, Hajmanouchehri R, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clinical Neuropharmacology 2011;34(4):174-7. [MEDLINE: 21738025]
41. Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference. Neuropsychiatric Disease and Treatment 2010;6(1):17-28. [EMBASE: 2010222500]
42. Reuter U, Del Rio MS, Diener HC, Allais G, Davies B, Gendolla A, et al. Migraines with and without aura and their response to preventive therapy with topiramate. Cephalalgia 2010;30(5):543-51. [MEDLINE: 19732072]
43. Rodríguez-Leyva I, Sánchez-Aguilar M, Hernández-Sierra JF, Mandeville PB, Rodríguez Leyva MDR, Shiguetomi-Medina JM, et al. Topiramate vs. amitriptyline in prophylactic treatment of migraine: a controlled clinical trial. Revista Mexicana de Neurociencia 2010;11(5):338-42. [EMBASE: 2011173413]
44. Silberstein S, Karim R, Kamin M, Jordan D, Hulihan J. Topiramate prophylaxis in patients suffering from migraine with aura: results from a randomized, double-blind placebo-controlled trial. European Journal of Neurology 2002;9 Suppl 2:44.
45. Silberstein SD. Efficacy and safety of topiramate in migraine prevention: a dose-ranging, placebo-controlled, double-blind, multicenter study. Advanced Studies in Medicine 2003;3(6C):S565-8.
46. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23(8):820-4.
47. Ad Hoc Committee on the Classification of Headache of the National Institute of Neurological Diseases and Blindness. Classification of headache. JAMA 1962;179(9):717-8.
48. Alderson P, Green S, Higgins JPT, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Appendix 5b. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
49. Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of migraine. QJM 1996;89(1):77-84. [MEDLINE: 8730346]
50. Dalkara S, Karakurt A. Recent progress in anticonvulsant drug research: strategies for anticonvulsant drug development and applications of antiepileptic drugs for non-epileptic central nervous system disorders. Current Topics in Medicinal Chemistry 2012;12(9):1033-71. [MEDLINE: 22352861]
51. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Canadian Journal of Neurological Sciences 1993;20(2):131-7. [MEDLINE: 8334575]
52. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376(9741):645-55. [MEDLINE: 20416945]
53. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. European Journal of Neurology 2009;16(9):968-81. [MEDLINE: 19708964]
54. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380(9859):2163-96. [MEDLINE: 23245607]
55. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:1-160.
56. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96.
57. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [MEDLINE: 8721797]
58. Janssen-Cilag Topimax product information. LIF - the research based pharmaceutical industry; 2013. www.fass.se (accessed 15 March 2013).
59. Larsson B, Andrasik F. Relaxation treatment of recurrent headaches in children and adolescents. In: Guidetti V, Russell G, Sillanpää M, Winner P editor(s). Headache and Migraine in Childhood and Adolescence. London: Martin Dunitz, 2002:307-16.
60. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology 2012;19(5):703-11. [MEDLINE: 22136117]
61. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010610]
62. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010611]
63. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010609]
64. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010608]
65. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998.
66. Mehuys E, Paemeleire K, Van Hees T, Christiaens T, Van Bortel LM, Van Tongelen I, et al.Self-medication of regular headache: a community pharmacy-based survey. European Journal of Neurology 2012;19(8):1093-9. [MEDLINE: 22360745]
67. Olesen J, Bousser M-G, Diener H-C, Dodick D, First M, Goadsby PJ, et al. Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26(6):742-6. [MEDLINE: 16686915]
68. Porter RJ, Meldrum BS. Antiepileptic drugs. In: Katzung BG editor(s). Basic and Clinical Pharmacology. 5th Edition. Norwalk, CT: Appleton & Lange, 1992:331-49.
69. Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D'Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008;70(7):548-55. [MEDLINE: 18268247]
70. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337-45. [MEDLINE: 22529202]
71. Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D'Amico D, Diener HC, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32(1):6-38. [MEDLINE: 22384463]
72. Victor S, Ryan S. Drugs for preventing migraine headaches in children. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD002761]
73. Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001133.pub3]
74. Chronicle EP, Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD003226.pub2]
75. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008;28(6):585-97. [MEDLINE: 18454787]